Cantor Fitzgerald Estimates Korro Bio FY2026 Earnings

Korro Bio, Inc. (NASDAQ:KRRO) – Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Korro Bio in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the company will earn ($6.83) per share for the year. Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($2.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.60) by $0.11. The firm had revenue of $2.55 million during the quarter, compared to analyst estimates of $0.13 million.

A number of other brokerages also recently commented on KRRO. Oppenheimer lowered their target price on Korro Bio from $155.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 13th. Chardan Capital restated a “buy” rating and issued a $25.00 target price on shares of Korro Bio in a research note on Tuesday, May 13th. HC Wainwright lowered their target price on Korro Bio from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Finally, Royal Bank of Canada lowered their target price on Korro Bio from $105.00 to $95.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 19th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $102.43.

Korro Bio Stock Performance

Shares of KRRO stock opened at $14.87 on Tuesday. The stock’s 50-day simple moving average is $14.66 and its 200-day simple moving average is $27.28. The firm has a market capitalization of $139.64 million, a PE ratio of -1.58 and a beta of 2.45. Korro Bio has a fifty-two week low of $10.29 and a fifty-two week high of $98.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS purchased a new position in Korro Bio during the fourth quarter worth approximately $53,000. Quarry LP purchased a new position in Korro Bio during the first quarter worth approximately $35,000. AlphaQuest LLC boosted its position in Korro Bio by 23.2% during the fourth quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock worth $83,000 after purchasing an additional 412 shares in the last quarter. Wells Fargo & Company MN boosted its position in Korro Bio by 32.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,392 shares of the company’s stock worth $129,000 after purchasing an additional 831 shares in the last quarter. Finally, Deutsche Bank AG boosted its position in Korro Bio by 29.4% during the fourth quarter. Deutsche Bank AG now owns 4,110 shares of the company’s stock worth $156,000 after purchasing an additional 935 shares in the last quarter. Hedge funds and other institutional investors own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).